Radius Health Announces the Appointment of Bethany Sensenig as Chief Financial Officer
BOSTON, MA, SEPTEMBER 26, 2023––(BUSINESS WIRE)––Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused on bone health and related areas, announced today the appointment of Bethany Sensenig to the role of Chief Financial Officer, reporting to the Company’s Chief Executive Officer, Scott Briggs.
“The addition of Bethany to the Radius Leadership Team is a testament to our efforts to bring onboard talented and highly experienced pharmaceutical professionals who can support both our commercial efforts and longer-term growth plans,” said Mr. Briggs. “I am particularly excited to welcome Bethany as she brings over twenty years of business and strategic financial leadership to Radius, with both private and public pharmaceutical and biotech companies, and has supported numerous business and corporate transactions. These are skills that are essential to our future growth plans.”
“Additionally, I want to thank Mark Conley for his contributions to the organization. Mark has played a particularly important role in the transition of Radius to a private company over the last year, and we wish him well in his future endeavors.”
Ms. Sensenig added, “I am excited for this opportunity at Radius to use my background, experience, and strategic focus to meaningfully contribute to a strong and growing commercial business. I look forward to working closely with Scott and the leadership team to drive the Company’s future growth and business development efforts going forward.”
Ms. Sensenig was most recently Chief Financial Officer and Interim Chief Executive Officer of 9 Meters Biopharma, a clinical-stage biotechnology company. Prior to that, Ms. Sensenig was Chief Financial Officer and Head of U.S. Operations of Minovia Therapeutics, Ltd., a privately held biotechnology company, where she played a critical leadership role in building the company’s business and financing strategy. She spent 13 years at Biogen Inc., a multinational biotechnology company, where she held several positions of increasing responsibility, the latest of which was Vice President of Finance and Commercial Operations. Ms. Sensenig has played key roles in numerous transactions and acquisition-related deals totaling over $2 billion across Biogen and Minovia and had direct P&L accountability at Biogen for upwards of $1 billion in annual revenue across 30 countries spanning the U.S., Asia-Pacific, Latin America, and Europe. Earlier in her career, Ms. Sensenig held financial management and analyst roles at Merck & Co. Inc. and Nexus Technologies, Inc. Ms. Sensenig also serves as a director and audit committee member of the Board for Supernus Pharmaceuticals.
Ms. Sensenig holds a Bachelor of Science in Accounting and Business Management from Montreat College, a Master of Business Administration from Western Carolina University, and is a Certified Management Accountant.
About Radius:
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also recently announced an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company’s presence in bone health.
Contact:
Sara Goldberg: Lead, Communications
Email: [email protected]
Phone: +1 (631) 379-8374